RxDoctor Payments Data

Denise Garee, PhD

Family · Vero Beach, FLNPI 1467195602

Payments from drug & device makers

$1,453in general payments, 2019–2025

Across 34 payments — averaging $42.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$261
  • GSK$240
  • Amgen$212
  • Astellas Pharma US Inc$125
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$118
  • Bsn Medical Inc$113
  • plus $384 from 7 others

What the payments were for

  • Food & beverage$1,453100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,453 in reported general payments places this provider in the 75th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$80,451
Medicare patients
343
Services billed
930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$50,149
EliquisApixaban30$45,403
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$19,169
TrulicityDulaglutide14$16,746
MounjaroTirzepatide11$11,210
Arnuity ElliptaFluticasone Furoate11$4,771
Rosuvastatin Calcium149$2,676
SymbicortBudesonide/Formoterol Fumarate11$2,629
Levothyroxine Sodium235$2,340
Atorvastatin Calcium282$2,281
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,899
Trazodone Hcl79$1,732
Omeprazole114$1,729
Albuterol Sulfate HfaAlbuterol Sulfate79$1,723
Losartan Potassium137$1,477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$53$50,14944 claims
Lilly USA, LLCTrulicity, Mounjaro$51$27,95625 claims
GSKTrelegy Ellipta, Arnuity Ellipta$240$23,94027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 14,618 family providers in Florida.

Other family in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →